

.....
**Report of the WHO
Informal Consultation
on monitoring of
drug efficacy in the control
of schistosomiasis
and intestinal nematodes**

.....
**Geneva
8–10 July 1998**



**Schistosomiasis and Intestinal Parasites Control Team
Planning and Technical Guidance
Communicable Diseases Prevention and Control
www.who.ch/cds**

(Formerly: Schistosomiasis and Intestinal Parasites Unit of the Division of Control of Tropical Diseases)

REPORT OF THE
WHO INFORMAL CONSULTATION ON
MONITORING OF DRUG EFFICACY IN THE
CONTROL OF SCHISTOSOMIASIS AND INTESTINAL NEMATODES

GENEVA
8-10 July 1998

Schistosomiasis and Intestinal Parasites Control Team
Planning and Technical Guidance
Communicable Diseases Prevention and Control
www.who.ch/cds
(Formerly: Schistosomiasis and Intestinal Parasites Unit of the
Division of Control of Tropical Diseases)

This Consultation was financially supported by:

Direzione Generale Cooperazione allo Sviluppo
Italian Ministry of Foreign Affairs

TABLE OF CONTENTS

	Page no.
LIST OF PARTICIPANTS.....	4
PREFACE	8
1. PURPOSE OF THE CONSULTATION	10
2. ROLE OF CHEMOTHERAPY IN CURRENT STRATEGIES FOR CONTROLLING MORBIDITY DUE TO SCHISTOSOMIASIS AND INTESTINAL NEMATODE INFECTIONS	11
3. AVAILABLE DRUGS AND MEASURES OF THEIR EFFICACY	12
3.1 ALBENDAZOLE	14
3.2 IVERMECTIN	15
3.3 LEVAMISOLE	15
3.4 MEBENDAZOLE	15
3.5 OXAMNIQUINE.....	16
3.6 PRAZIQUANTEL	17
3.7 PYRANTEL	17
3.8 DRUG COMBINATIONS	17
3.9 ROLE OF TRADITIONAL MEDICINE IN THE TREATMENT OF HELMINTH INFECTIONS	18
3.9.1 <i>Experience from China</i>	19
4. THEORETICAL BASIS FOR THE EMERGENCE OF ANTHELMINTHIC DRUG RESISTANCE	20
5. RESISTANCE OF SCHISTOSOMES AND INTESTINAL NEMATODES TO ANTHELMINTHIC DRUGS	21
5.1 SCHISTOSOMES AND PRAZIQUANTEL IN SENEGAL	21
5.2 SCHISTOSOMES, OXAMNIQUINE AND PRAZIQUANTEL	22
5.3 SCHISTOSOMES AND METRIFONATE.....	24
5.4 HOOKWORM INFECTIONS.....	24
5.5 RESISTANCE IN NEMATODES OF VETERINARY IMPORTANCE	24
6. GUIDELINES AND RECOMMENDATIONS	26
6.1 AN APPROACH TO THE PREVENTION OF DRUG RESISTANCE.....	27
6.1.1 <i>Drug quality</i>	27
6.1.2 <i>Drug distribution and usage</i>	27
6.1.3 <i>Design of control strategy</i>	28
6.1.4 <i>Recommendation on drug issues</i>	28
6.2 MONITORING THE DEVELOPMENT OF DRUG RESISTANCE IN THE COMMUNITY	28
6.2.1 <i>Recommended procedure</i>	29

6.2.2	<i>Recommended Drug Dosages</i>	30
6.3	TESTING FOR DRUG RESISTANCE IN THE LABORATORY.....	31
6.3.1	<i>Recommendations</i>	31
REFERENCES		33
ANNEX 1 DRUG QUALITY ASSURANCE ISSUES		37
ANNEX 2 COUNTRY EXPERIENCE OF HELMINTH CONTROL PROGRAMMES		39
ACKNOWLEDGEMENTS		45

List of Participants

Dr Suleiman M. Al-Seghayer, Assistant Director-General for Parasitic Diseases, Ministry of Health, P.O. Box No. 103091, Riyadh 11695, Saudi Arabia

Dr Marco Albonico, Specialist in Infectious Diseases, Fondazione Ivo de Carneri, Via IV Marzo 14, 10122 Turin, Italy

Dr James L. Bennett, Professor, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA

Professor Donald A.P. Bundy, WHO Collaborating Centre for the Epidemiology of Intestinal Parasitic Infections, The Wellcome Trust Centre for the Epidemiology of Infectious Disease, University of Oxford, South Parks Road, Oxford OX1 3PS, United Kingdom (Co-Chairman)

Dr Donato Cioli, Laboratory of Cell Biology, Istituto di Biologia Cellulare, Viale Marx 43, 00137 Rome, Italy

Professor D.W.T. Crompton, Head, WHO Collaborating Centre for Soil-transmitted Helminthiases, Graham Kerr Building, University of Glasgow, Glasgow, Scotland, United Kingdom (Rapporteur)

Dr Taha Abdel Gawad El-Khoby, Under-Secretary, Endemic Diseases Sector, Ministry of Health and Population, 3 Magles El Shaab Street, Garden City, Cairo, Giza, Egypt

Professor Hermann Feldmeier, Epidemiology Working Group, Faculty of Medicine, Free University of Berlin, Fabeckstrasse 60, 12203 Berlin, Germany

Dr Bruno Gryseels, Director, Prince Leopold Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium

Dr Helen Guyatt, WHO Collaborating Centre for the Epidemiology of Intestinal Parasitic Infections, The Wellcome Trust Centre for the Epidemiology of Infectious Disease, University of Oxford, South Parks Road, Oxford OX1 3PS, United Kingdom

Professor Mahroof Ismail, Department of Parasitology, Faculty of Medicine,
University of Colombo, Kynsey Road, Colombo 8, Sri Lanka (Co-
Chairman)

Dr Uledi Mwita Kisumku, Principal Secretary, Ministry of Health, P.O. Box
236, Zanzibar, United Republic of Tanzania

Professor Peng Weidong, Department of Parasitology, Jiangxi Medical
College, Nanchang, Jiangxi 33006, People's Republic of China

Dr Marleen Roos, Agricultural Research Department, Institute for Animal
Science and Health, P.O. Box 65, 8200 AB Lelystad, The Netherlands

Dr Ronaldo Santos do Amaral, Gerência Técnica de Equistossomose - FNS -
MS SAS Q4 BL "N", SL 715, CEP: 79958-902, Brasília DF, Brazil

Dr Xiao Shuhua, Institute of Parasitic Diseases, Chinese Academy of
Preventive Medicine, 207 Rui Jin Er Lu, Shanghai 200025, People's
Republic of China

Dr Vaughan R. Southgate, WHO Collaborating Centre for the Identification
and Characterization of Schistosome Strains and their Snail Intermediate
Hosts, Department of Zoology, The Natural History Museum, Cromwell
Road, South Kensington, London, W7 5BD, United Kingdom

Professor Martin Geoffrey Taylor, Professor of Medical Helminthology,
WHO Collaborating Centre for Research and Training on
Schistosomiasis, Department of Infectious and Tropical Diseases,
London School of Hygiene and Tropical Medicine, Keppel Street,
London WC1E 7HT, United Kingdom (Rapporteur)

Dr Michael A. Taylor, Head, Parasitology Central Veterinary Laboratory,
Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, United
Kingdom

Professor R.C.A. Thompson, WHO Collaborating Centre for the Molecular
Epidemiology of Parasitic Infections and Institute for Molecular Genetics
and Animal Disease, Division of Veterinary and Biomedical Sciences,
Murdoch University, South Street, Murdoch 6150, Western Australia

Observers

Dr Joachim A. Ernst, Head, Community Treatment and Institutional Relations Bayer AG, Business group Pharma, 51368 Leverkusen, Germany

German Pharma Health Fund e.V. (GPHF), Kennedyallee 111, 60596 Frankfurt am Main, Germany (represented by Dr Joachim Ernst)

Dr Michelle Harrison, Executive Director, Johnson & Johnson Institute for Children, One Johnson & Johnson Plaza, New Brunswick, NJ 08933, USA

Dr J. Horton, SmithKline Beecham, SmithKline House, Great West Road, Brentford TW8 9BD, United Kingdom

Dr Chantal Laburte, Product Information Manager, Novartis Pharma Inc., Drug Regulatory Affairs, K-402.5.24, 4002 Basel, Switzerland

****Mr Doug McIntosh, Medical Marketing and Communications, Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom**

Dr O. Morin, International Federation of Pharmaceutical Manufacturers Associations, 30 rue de St-Jean, P.O. Box 9, 1211 Geneva 18, Switzerland

Sr Maura O'Donohue, M.D., Director of Programming, Catholic Medical Mission Board, Inc., 10 West 17th Street, New York, N.Y. 10011-5765, USA

Dr Manouchehr Yazhari, SmithKline Beecham, SmithKline House, Great West Road, Brentford TW8 9BD, United Kingdom

Specialized Agencies and related Organizations

**** UNESCO - Dr Annar Cassam, Director, Liaison Office at Geneva**

UNICEF - Dr Hanna Dal Badawan, Technical Officer, UNICEF Somalia

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30551

